Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone

Haematologica

Volumn 100, Issue 10, 2015, Pages 1327-1333

  Dimopoulos, Meletios A ^a   Weise, Katja C ^b   Song, Kevin W ^c   Delforge, Michel ^d   Karlin, Lionel ^e   Goldschmidt, Hartmut ^f   Moreau, Philippe ^g   Banos, Anne ^h   Oriol, Albert ⁱ   Garderet, Laurent ^j   Cavo, Michele ^k   Ivanova, Valentina ^l   Alegre, Adrian ^m   Martinez Lopez, Joaquin ⁿ   Chen, Christine ^o   Spencer, Andrew ^p   Knop, Stefan ^q   Bahlis, Nizar J ^r   Renner, Christoph ^s   Yu, Xin ^t   Hong, Kevin ^t   Sternas, Lars ^t   Jacques, Christian ^t   Zaki, Mohamed H ^t   San Miguel, Jesus F ^u   more..

^a ALEXANDRA HOSPITAL   (Greece)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e CENTRE HOSPITALIER LYON SUD   (France)

^f GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^g HÔTEL DIEU   (France)

^h CENTRE HOSPITALIER DE LA CÔTE BASQUE   (France)

ⁱ CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^j HÔPITAL SAINT ANTOINE   (France)

^k UNIVERSITY OF BOLOGNA   (Italy)

^l Russia   (Russian Federation)

^m HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

ⁿ HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^o PRINCESS MARGARET HOSPITAL   (Canada)

^p ALFRED HOSPITAL   (Australia)

^q UNIVERSITY OF WÜRZBURG   (Germany)

^r UNIVERSITY OF CALGARY   (Canada)

^s UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^t CELGENE CORPORATION   (United States)

^u UNIVERSITY CLINIC OF NAVARRA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DEXAMETHASONE; HEMOGLOBIN; LACTATE DEHYDROGENASE; LOW MOLECULAR WEIGHT HEPARIN; POMALIDOMIDE; ANTINEOPLASTIC AGENT; THALIDOMIDE;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BONE PAIN; CANCER RECURRENCE; CHROMOSOME ABERRATION; CONTROLLED STUDY; CYTOGENETICS; DRUG DOSE COMPARISON; DRUG SAFETY; FATIGUE; FOLLOW UP; GLUCOSE INTOLERANCE; HUMAN; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VERY ELDERLY; ANALOGS AND DERIVATIVES; CANCER STAGING; CLINICAL TRIAL; FEMALE; GENETICS; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RECURRENT DISEASE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOSOME ABERRATIONS; DEXAMETHASONE; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; PROGNOSIS; RECURRENCE; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84943235889     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.117077     Document Type: Article

References (28)

1. Palumbo A, Rajkumar SV, San Miguel JF, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014;32(6):587-600.
2. Engelhardt M, Terpos E, Kleber M, et al. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica. 2014;99(2):232-242.
3. Pulte D, Gondos A, Brenner H. Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data. Oncologist. 2011;16(11):1600-1603.
4. Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter International Myeloma Working Group study. Leukemia. 2012;26(1):149-157.
5. Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood. 2007;109(8):3489-3495.
6. Avet-Loiseau H, Hulin C, Campion L, et al. Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the Intergroupe Francophone du Myélome experience. J Clin Oncol. 2013;31(22):2806-2809.
7. Avet-Loiseau H, Soulier J, Fermand JP, et al. Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone. Leukemia. 2010;24(3):623-628.
8. Chesi M, Nardini E, Brents LA, et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet. 1997;16(3):260-264.
9. Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM, Bergsagel PL. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood. 1998;92(9):3025-3034.
10. Chesi M, Brents LA, Ely SA, et al. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood. 2001;97(3):729-736.
11. Lode L, Eveillard M, Trichet V, et al. Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. Haematologica. 2010;95(11):1973-1976.
12. Jakubowiak AJ, Siegel DS, Martin T, et al. Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving singleagent carfilzomib in the PX-171-003-A1 study. Leukemia. 2013;27(12):2351-2356.
13. Klein U, Jauch A, Hielscher T, et al. Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone. Cancer. 2011;117(10):2136-2144.
14. Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDs) in multiple myeloma. Leukemia. 2010;24(1):22-32.
15. Richardson PG, Siegel DS, Vij R, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014;123(12):1826-1832.
16. Leleu X, Karlin L, Macro M, et al. Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results. Blood. 2015;125(9):1411-1417.
17. San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(11):1055-1066.
18. Durie BG, Harousseau J, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9): 1467-1473.
19. Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102(5): 1115-1123.
20. Hartmann L, Biggerstaff JS, Chapman DB, et al. Detection of genomic abnormalities in multiple myeloma: the application of FISH analysis in combination with various plasma cell enrichment techniques. Am J Clin Pathol. 2011;136(5):712-720.
21. Siegel DS, Martin T, Singhal S, et al. Response rates to single-agent carfilzomib in patients refractory or intolerant to both bortezomib and immunomodulators in trial PX-171-003-A1. J Clin Oncol. 2012;30(15 suppl):518s. Abstract 8035.
22. Leleu X, Attal M, Arnulf B, et al. Pomalidomide plus low dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02. Blood. 2013;121(11): 1968-1975.
23. Leleu X, Karlin L, Macro M, et al. Pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma (RRMM) with deletion (del)17p and/or translocation t(4;14). Blood. 2013;122(21):Abstract 689.
24. Chang H, Trieu Y, Qi X, Xu W, Stewart KA, Reece D. Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma. Leuk Res. 2007;31(6):779-782.
25. Avet-Loiseau H, Leleu X, Roussel M, et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol. 2010;28(30):4630-4634.
26. Neben K, Lokhorst HM, Jauch A, et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood. 2012;119(4):940-948.
27. Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet. 2010;376(9758):2075-2085.
28. Shaughnessy JD, Zhou Y, Haessler J, et al. TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3. Br J Haematol. 2009;147(3):347-351.